Evidence map›Paper›PMID 28101585›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2017

Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.

Filip Poelaert, Valérie Fonteyne, Piet Ost, Bart De Troyer, Karel Decaestecker, Gert De Meerleer, Pieter De Visschere, Tom Claeys, Bert Dhondt, Nicolaas Lumen

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Postoperative radiotherapy for prostate cancer : Morbidity of local-only or local-plus-pelvic radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Filip PoelaertDepartment of Urology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium. filip.poelaert@uzgent.be.ORCID http://orcid.org/0000-0002-2213-6211
Valérie FonteyneDepartment of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Piet OstDepartment of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Bart De TroyerDepartment of Urology, AZ Nikolaas, Sint-Niklaas, Belgium.
Karel DecaesteckerDepartment of Urology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.
Gert De MeerleerDepartment of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
Pieter De VisschereDepartment of Radiology, Ghent University Hospital, Ghent, Belgium.
Tom ClaeysDepartment of Urology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.
Bert DhondtDepartment of Urology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.
Nicolaas LumenDepartment of Urology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe goal of this work was to investigate the oncological outcome of whole pelvis radiotherapy (wpRT) in pathologic pelvic lymph node-positive (pN1) prostate cancer (PCa), evaluate the location of relapse, and identify potential prognostic factors. PATIENTS AND

methodsAll patients undergoing pelvic lymph node dissection (PLND) since the year 2000 at a single tertiary care center were evaluated. A total of 154 patients with pN1 PCa were treated with wpRT (39 in an adjuvant setting) and 2-3 years of androgen deprivation therapy (ADT). Kaplan-Meier analysis was performed to estimate biochemical recurrence-free survival (bRFS), clinical progression-free survival (cPFS), and prostate cancer-specific survival (CSS). Uni- and multivariate regression analyses were performed to identify prognostic factors.

resultsEstimated bRFS was 67%, cPFS was 71%, and CSS was 96% at 5 years. Median follow-up was 55 months (interquartile range 25-87). Multivariate analysis identified having only 1 positive lymph node, a shorter time between diagnosis and PLND, and older age as independent favorable prognostic factors for biochemical and clinical recurrence. The number of positive lymph nodes was prognostic for CSS (hazard ratio [HR] 1.34, 95% confidence interval 1.17-1.54) and OS (HR 1.22, 95% confidence interval 1.10-1.36). Bone metastases were the most frequent location of PCa relapse (n = 32, 64%).

conclusionsPatients with pN1 PCa treated with wpRT and 2-3 years ADT have an encouraging 5‑year CSS. Understaging of the disease extent may be the most important enemy in definitive pN1 PCa treatment.

Indexed as

AgedAndrogen AntagonistsCombined Modality TherapyDisease-Free SurvivalFollow-Up StudiesHumansKaplan-Meier EstimateLymphatic MetastasisLymph Node ExcisionMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPelvisPrognosisAndrogen AntagonistsLymph node metastasesProstate cancerRadical prostatectomyRadiotherapySurvival analysis

Identifiers

PMID28101585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.